Astec Lifesciences Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Astec Lifesciences’ record is marked by a deep restatement of equity, persistent cash losses, and governance votes that repeatedly split almost evenly. A ₹222 crore opening-retained-earnings restatement in FY26 rewrites the base from which losses are measured, while operating cash flow has covered only half of cumulative EBITDA over six years. The company raised ₹249 crore through a rights issue in July 2025 to repair its balance sheet, yet receivable days have more than doubled to 202 and shareholder resolutions on related-party transactions continue to pass by margins of barely three percentage points.

Key findings

  1. Opening retained earnings were restated downward by ₹222 crore in FY26 Major - Retained earnings as at 1 April 2025 were reduced from 141.12 crore to a deficit of 80.92 crore, a restatement of 222.04 crore attributed to a prior period error or change in accounting policy. The company did not recognise deferred tax assets of ₹20.02 crore on tax losses of ₹79.56 crore because it is not probable that future taxable profit will be available. An incremental employee compensation cost arising from the Labour Codes notified on 21 November 2025 was presented under “Exceptional Items” in the FY26 profit and loss.
  2. Operating cash flow covered only half of cumulative EBITDA over six years Major - Cumulative CFO of ₹279 crore over FY21-FY26 covered only 50% of cumulative EBITDA of ₹558 crore. In FY26, standalone net loss was ₹81.01 crore and CFO was negative ₹80.71 crore. ROCE turned negative at -5.54% in FY26 and -13.21% in FY25, down from 7.32% in FY23. The company raised ₹249.35 crore through a rights issue in July 2025, with proceeds designated for repayment or prepayment of borrowings and general corporate purposes.
  3. Receivable days more than doubled to 202, yet loss allowances were recorded Major - Receivable days rose from 90 in FY22-23 to 135 in FY23-24, 141 in FY24-25, and 202 in FY25-26. Revenue recognition was identified as a Key Audit Matter in the standalone and consolidated auditor’s reports for FY21-22, FY23-24, and FY24-25. The company states there were no disputed trade receivables in FY22-23, FY23-24, and FY24-25, but loss allowances of ₹1.98 lakh were recorded in FY22-23 and ₹7.81 lakh in FY23-24.
  4. RPT resolutions passed by razor-thin margins after one outright failure Major - At the 28 July 2025 AGM, the ordinary resolution to approve RPTs with Godrej Agrovet Limited for FY25-26 up to ₹400 Crore failed with 45.80% in favour and 54.20% against. The same resolution was re-submitted via postal ballot and passed on 7 November 2025 with 50.87% votes in favour and 49.13% against. For FY26-27, the resolution to approve RPTs with Godrej Agrovet Limited up to ₹300 Crore passed on 4 July 2026 with 52.86% in favour and 47.14% against, while public institutional shareholders voted 77.90% against.
  5. CARO reports record cash losses, and the FY26 consolidated CARO flags unfavourable remarks Major - CARO cash losses were ₹25.66 crore in FY23-24, ₹94.11 crore in FY24-25, and 37.71 crore in FY25-26. The FY25-26 consolidated auditor’s report states that “Companies incorporated in India included in the consolidated financial statements have unfavourable remarks, qualifications or adverse remarks in their respective CARO reports”. The statutory auditor issued an unqualified opinion on standalone and consolidated financial statements every year from FY20-21 through FY25-26.
  6. A ₹132 crore excise duty dispute has been pending for over a decade Minor - Contingent liabilities as at 31 March 2026 include excise duty demands of 132.03 crore, up from 125.95 crore in the prior year. Excise duty disputes of 62.39 crore and 66.42 crore for FY08-09 to FY13-14 are pending before CESTAT and the High Court respectively as at 31 March 2026. On 31 July 2025, the company received a Show Cause cum Demand Notice alleging erroneous sanction of a GST refund of ₹41.12 crore for April 2019 to March 2022 and demanding recovery with interest and penalty.
  7. A single exchange penalty of ₹5.19 lakh for a delayed independent director appointment was paid Minor - NSE and BSE each imposed a penalty of ₹2,59,600 on the company in FY24-25 for delayed compliance with Regulation 17(1)(b) of the Listing Regulations following a three-month independent director vacancy; the penalties were duly paid. No significant or material orders from regulators, courts, or tribunals adversely impacting going concern status were passed during FY25-26.

What to watch

Bottom line: This is a disclosed but deeply strained record: a ₹222 crore equity restatement resets the earnings baseline, cash losses persist despite a ₹249 crore rights-issue repair, and governance resolutions pass on margins that leave nearly half the vote in dissent. The risk is not hidden, it sits in the widening gap between reported revenue and collected cash, and in the concentrated related-party relationships that sustain the company’s funding. Watch the GST and excise outcomes, the holding company’s CARO resolution, and whether the next RPT vote breaks the pattern.